JP2007504830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504830A5 JP2007504830A5 JP2006526347A JP2006526347A JP2007504830A5 JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5 JP 2006526347 A JP2006526347 A JP 2006526347A JP 2006526347 A JP2006526347 A JP 2006526347A JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- composition
- oligonucleotide
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 11
- 229920000272 Oligonucleotide Polymers 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 108010017842 Telomerase Proteins 0.000 claims 6
- 102000004591 Telomerase Human genes 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 230000000295 complement Effects 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108010057210 telomerase RNA Proteins 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 3
- 125000003835 nucleoside group Chemical group 0.000 claims 3
- 239000000546 pharmaceutic aid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 150000002632 lipids Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- -1 fatty acid compound Chemical class 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
Claims (37)
- 以下の構造:
O−(x−L)n
を含む化合物であって、
Oは、ヒトテロメラーゼRNA配列(配列番号1)に対して相補的な、少なくとも5塩基を含む、オリゴヌクレオチドであり;
xは、任意のリンカーであり;
Lは、脂質部分であり;
そしてnは、1〜5の整数であり、n>1である場合、各々の(x−L)成分は独立して選択される、化合物。 - 請求項1に記載の化合物であって、Oは、ヒトテロメラーゼRNA配列(配列番号1)に対して相補的な、少なくとも10塩基を含む、化合物。
- 請求項2に記載の化合物であって、Lは、置換脂肪酸、非置換脂肪酸およびステロールからなる群より選択される脂質を含む、化合物。
- 請求項3に記載の化合物であって、Lは、フッ素で置換された脂肪酸である、化合物。
- 請求項2に記載の化合物であって、Lは、置換炭化水素もしくは非置換炭化水素である、化合物。
- 請求項5に記載の化合物であって、Lは、フッ素で置換された炭化水素である、化合物。
- 請求項1に記載の化合物であって、n=1であり、そして前記x−L成分は、前記オリゴヌクレオチドOの5’末端に対して共有結合する、化合物。
- 請求項1に記載の化合物であって、n=1であり、そして前記(x−L)成分は、前記オリゴヌクレオチドOの3’末端に対して共有結合する、化合物。
- 請求項1に記載の化合物であって、n=2であり、1つの独立して選択された(x−L)成分は前記5’末端に共有結合し、そして1つの独立して選択された(x−L)成分は前記3’末端に共有結合する、化合物。
- 請求項1に記載の化合物であって、n=1であり、そして前記(x−L)成分は前記オリゴヌクレオチドOの核酸塩基に共有結合する、化合物。
- 請求項1に記載の化合物であって、前記オリゴヌクレオチドOのヌクレオシド間の結合は、N3’→P5’ホスホラミデート結合である、化合物。
- 請求項1に記載の化合物であって、前記オリゴヌクレオチドOのヌクレオシド間の結合は、N3’→P5’チオホスホラミデート結合である、化合物。
- 請求項1に記載の化合物であって、オリゴヌクレオチドOは、ヒトテロメラーゼRNA配列(配列番号1)に対して相補的な、少なくとも10塩基を含む、化合物。
- 請求項1に記載の化合物であって:
前記オリゴヌクレオチドOのヌクレオシド間の結合は、N3’→P5’チオホスホラミデート結合であり;
Oの配列は、ヒトテロメラーゼRNA配列(配列番号1)に対して相補的な、少なくとも12塩基を含み;
n=1であり;
(x−L)は、Oの5’末端もしくは3’末端に共有結合し;そして、
Lは、脂肪酸である、化合物。 - 請求項14に記載の化合物であって、xは、グリセロールリンカーもしくはアミノグリセロールリンカーである、化合物。
- 請求項14に記載の化合物であって、Lは、アミド結合を通じて前記オリゴヌクレオチドOの3’末端に直接的に結合する、化合物。
- テロメラーゼ酵素の活性を阻害するための、請求項1に記載の化合物を含む、組成物。
- テロメラーゼ酵素の活性を阻害するための、請求項16に記載の化合物を含む、組成物。
- テロメラーゼ酵素の活性を阻害するための、請求項18に記載の化合物を含む、組成物。
- 細胞内においてテロメラーゼ酵素の活性を阻害するための、請求項1に記載の化合物を含む、組成物。
- 細胞内においてテロメラーゼ酵素の活性を阻害するための、請求項16に記載の化合物を含む、組成物。
- 細胞内においてテロメラーゼ酵素の活性を阻害するための、請求項18に記載の化合物を含む、組成物。
- 請求項22〜24のいずれか1項に記載の組成物であって、前記細胞は、癌細胞である、組成物。
- 癌細胞の増殖を阻害するための、請求項1に記載の化合物を含む、組成物。
- 癌細胞の増殖を阻害するための、請求項16に記載の化合物を含む、組成物。
- 癌細胞の増殖を阻害するための、請求項18に記載の化合物を含む、組成物。
- 薬学的に受容可能な賦形剤で処方される、請求項1に記載の化合物を含む、薬学的組成物。
- 薬学的に受容可能な賦形剤で処方される、請求項16に記載の化合物を含む、薬学的組成物。
- 薬学的に受容可能な賦形剤で処方される、請求項18に記載の化合物を含む、薬学的組成物。
- 医薬の製造のための、請求項1に記載の化合物の使用。
- 医薬の製造のための、請求項16に記載の化合物の使用。
- 医薬の製造のための、請求項18に記載の化合物の使用。
- 癌を処置するための医薬の製造のための、請求項1に記載の化合物の使用。
- 癌を処置するための医薬の製造のための、請求項16に記載の化合物の使用。
- 癌を処置するための医薬の製造のための、請求項18に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50150903P | 2003-09-09 | 2003-09-09 | |
US60/501,509 | 2003-09-09 | ||
PCT/US2004/029718 WO2005023994A2 (en) | 2003-09-09 | 2004-09-09 | Modified oligonucleotides for telomerase inhibition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010286755A Division JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007504830A JP2007504830A (ja) | 2007-03-08 |
JP2007504830A5 true JP2007504830A5 (ja) | 2007-10-11 |
JP4690324B2 JP4690324B2 (ja) | 2011-06-01 |
Family
ID=34273050
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526347A Active JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2010286755A Active JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016014128A Active JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2018025362A Active JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2023086871A Pending JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications After (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010286755A Active JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016014128A Active JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2018025362A Active JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2023086871A Pending JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Country Status (20)
Country | Link |
---|---|
US (8) | US7494982B2 (ja) |
EP (3) | EP3682903A1 (ja) |
JP (10) | JP4690324B2 (ja) |
KR (3) | KR101298493B1 (ja) |
CN (2) | CN100393209C (ja) |
AU (2) | AU2004271215B2 (ja) |
BR (1) | BRPI0414222B8 (ja) |
CA (1) | CA2536015C (ja) |
CY (2) | CY1120113T1 (ja) |
DK (2) | DK3342425T3 (ja) |
ES (2) | ES2775525T3 (ja) |
HK (1) | HK1257622A1 (ja) |
HU (2) | HUE048359T2 (ja) |
IL (1) | IL173747A (ja) |
MX (1) | MXPA06002660A (ja) |
NZ (1) | NZ545516A (ja) |
PL (2) | PL1667522T3 (ja) |
PT (2) | PT1667522T (ja) |
SI (2) | SI1667522T1 (ja) |
WO (1) | WO2005023994A2 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3682903A1 (en) | 2003-09-09 | 2020-07-22 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
EP1694842B1 (en) | 2003-11-04 | 2011-03-23 | Geron Corporation | Rna amidates and thioamidates for rnai |
PT1778711T (pt) * | 2004-07-02 | 2017-10-19 | Geron Corp | Síntese de monómeros nucleosídeos 3'-amino protegidos |
WO2006113470A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
HUE041448T2 (hu) | 2006-10-30 | 2019-05-28 | Geron Corp | Kombinált telomerázgátló és gemcitabin rák kezelésére |
WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
US8507200B2 (en) | 2007-02-09 | 2013-08-13 | Northwestern University | Particles for detecting intracellular targets |
WO2008112129A2 (en) | 2007-03-09 | 2008-09-18 | Geron Corporation | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
DK2476689T3 (en) | 2007-05-10 | 2016-01-18 | Agilent Technologies Inc | Thiocarbonbeskyttende groups for RNA synthesis |
AU2008259907B2 (en) | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
CA2728762A1 (en) * | 2008-07-02 | 2010-01-07 | Enzon Pharmaceuticals, Inc. | Rna antagonists targeting hsp27 |
EP2175023A1 (en) * | 2008-07-31 | 2010-04-14 | The University of Zurich | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA |
HUE027213T2 (en) | 2008-10-17 | 2016-10-28 | Geron Corp | A method for identifying a patient's sensitivity to telomerase inhibitor therapy |
WO2010060110A1 (en) | 2008-11-24 | 2010-05-27 | Northwestern University | Polyvalent rna-nanoparticle compositions |
JP5645840B2 (ja) | 2008-12-02 | 2014-12-24 | 株式会社Wave Life Sciences Japan | リン原子修飾核酸の合成方法 |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
CN102596204B (zh) | 2009-07-06 | 2016-11-23 | 波涛生命科学有限公司 | 新的核酸前药及其使用方法 |
CN102666879B (zh) | 2009-10-30 | 2016-02-24 | 西北大学 | 模板化的纳米缀合物 |
WO2011079290A1 (en) * | 2009-12-24 | 2011-06-30 | Northwestern University | Oligonucleotide specific uptake of nanoconjugates |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
ES2656958T3 (es) | 2011-03-28 | 2018-03-01 | Geron Corporation | Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa |
JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
US9228189B2 (en) | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
CA3201145A1 (en) | 2012-10-26 | 2014-05-01 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
WO2014085632A1 (en) | 2012-11-30 | 2014-06-05 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
UA117116C2 (uk) | 2012-12-07 | 2018-06-25 | Джерон Корпорейшн | Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
IL240680B2 (en) | 2013-02-22 | 2023-03-01 | Univ Leland Stanford Junior | Nucleic acids encoding telomerase reverse transcriptase, preparations containing them and their uses |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3052512A4 (en) | 2013-09-30 | 2017-02-22 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
KR101766373B1 (ko) | 2015-01-05 | 2017-08-09 | 권영아 | 루테리온을 이용한 암세포의 텔로머라아제 억제방법 |
SI3286203T1 (sl) * | 2015-04-23 | 2020-10-30 | Geron Corporation | Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli |
EP3650546A1 (en) | 2015-07-29 | 2020-05-13 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutic oligonucleotides |
EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
MA45290A (fr) * | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
CA3059321A1 (en) * | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
PT3652187T (pt) * | 2017-07-10 | 2021-12-16 | Geron Corp | Processo melhorado para a preparação de imetelstat |
TW201919705A (zh) | 2017-07-28 | 2019-06-01 | 美商健生生物科技公司 | 治療骨髓增生不良症候群之方法 |
JPWO2021054370A1 (ja) * | 2019-09-18 | 2021-03-25 | ||
IL292327A (en) * | 2019-10-28 | 2022-06-01 | Geron Corp | Crystalline solids of 3-palmitoyl-amido-2,1-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrinylmethylether-propane and methods for their preparation and use |
KR20220088732A (ko) * | 2019-10-28 | 2022-06-28 | 제론 코포레이션 | 비정질 고체 석신일화 3-(지방산 아미도)-2-하이드록시-1-(보호된 하이드록시)-프로판 염 및 이를 제조하는 방법 |
WO2022186350A1 (ja) * | 2021-03-03 | 2022-09-09 | 国立大学法人東京大学 | 非環式スレオニノール核酸 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
EP0462145B1 (en) | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
EP0537299A1 (en) * | 1990-03-29 | 1993-04-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
US5419966A (en) * | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
US7067497B2 (en) * | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
EP1683863A3 (en) | 1993-10-18 | 2006-08-02 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
AU704549B2 (en) | 1994-03-18 | 1999-04-29 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
DE69534568T2 (de) | 1994-07-07 | 2006-07-27 | Geron Corp., Menlo Park | Säugetier-telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
CN1165508A (zh) | 1994-11-07 | 1997-11-19 | 海布里顿公司 | 利用3h-1,2-苯并二硫酚-3-1,1二氧化物合成35s-标记的寡核苷酸 |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
AU2445997A (en) | 1996-04-10 | 1997-10-29 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
WO1998028442A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
DE60038495T2 (de) | 1999-09-10 | 2009-04-09 | Geron Corp., Menlo Park | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
EP3682903A1 (en) | 2003-09-09 | 2020-07-22 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
PT1778711T (pt) | 2004-07-02 | 2017-10-19 | Geron Corp | Síntese de monómeros nucleosídeos 3'-amino protegidos |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2007127163A2 (en) | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
HUE041448T2 (hu) | 2006-10-30 | 2019-05-28 | Geron Corp | Kombinált telomerázgátló és gemcitabin rák kezelésére |
-
2004
- 2004-09-09 EP EP19209408.4A patent/EP3682903A1/en active Pending
- 2004-09-09 CN CNB2004800259754A patent/CN100393209C/zh active Active
- 2004-09-09 CN CN200810098490.8A patent/CN101293908B/zh active Active
- 2004-09-09 EP EP04783801.6A patent/EP1667522B1/en active Active
- 2004-09-09 KR KR1020137007201A patent/KR101298493B1/ko active IP Right Grant
- 2004-09-09 US US10/938,184 patent/US7494982B2/en active Active
- 2004-09-09 JP JP2006526347A patent/JP4690324B2/ja active Active
- 2004-09-09 DK DK17200625.6T patent/DK3342425T3/da active
- 2004-09-09 SI SI200432432T patent/SI1667522T1/en unknown
- 2004-09-09 WO PCT/US2004/029718 patent/WO2005023994A2/en active Application Filing
- 2004-09-09 PT PT4783801T patent/PT1667522T/pt unknown
- 2004-09-09 NZ NZ545516A patent/NZ545516A/en unknown
- 2004-09-09 EP EP17200625.6A patent/EP3342425B1/en active Active
- 2004-09-09 HU HUE17200625A patent/HUE048359T2/hu unknown
- 2004-09-09 HU HUE04783801A patent/HUE036593T2/hu unknown
- 2004-09-09 KR KR1020067004864A patent/KR20060132802A/ko not_active Application Discontinuation
- 2004-09-09 MX MXPA06002660A patent/MXPA06002660A/es active IP Right Grant
- 2004-09-09 SI SI200432487T patent/SI3342425T1/sl unknown
- 2004-09-09 PL PL04783801T patent/PL1667522T3/pl unknown
- 2004-09-09 DK DK04783801.6T patent/DK1667522T3/en active
- 2004-09-09 BR BRPI0414222A patent/BRPI0414222B8/pt active IP Right Grant
- 2004-09-09 ES ES17200625T patent/ES2775525T3/es active Active
- 2004-09-09 CA CA2536015A patent/CA2536015C/en active Active
- 2004-09-09 KR KR1020117017803A patent/KR101319388B1/ko active IP Right Grant
- 2004-09-09 AU AU2004271215A patent/AU2004271215B2/en active Active
- 2004-09-09 PL PL17200625T patent/PL3342425T3/pl unknown
- 2004-09-09 ES ES04783801.6T patent/ES2662196T3/es active Active
- 2004-09-09 PT PT172006256T patent/PT3342425T/pt unknown
-
2006
- 2006-02-15 IL IL173747A patent/IL173747A/en active IP Right Grant
-
2008
- 2008-11-21 US US12/276,127 patent/US20090286853A1/en not_active Abandoned
-
2009
- 2009-10-07 AU AU2009222616A patent/AU2009222616A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/886,080 patent/US20120129918A1/en not_active Abandoned
- 2010-12-22 JP JP2010286755A patent/JP5923241B2/ja active Active
-
2011
- 2011-12-15 JP JP2011274595A patent/JP2012085648A/ja active Pending
-
2012
- 2012-08-21 US US13/590,511 patent/US9404112B2/en active Active
-
2014
- 2014-04-21 JP JP2014087190A patent/JP2014158490A/ja active Pending
-
2015
- 2015-05-18 US US14/714,732 patent/US9657296B2/en active Active
- 2015-05-22 US US14/720,466 patent/US9388415B2/en active Active
- 2015-05-22 US US14/720,467 patent/US9388416B2/en active Active
-
2016
- 2016-01-28 JP JP2016014128A patent/JP6158966B2/ja active Active
- 2016-06-27 US US15/194,230 patent/US10196641B2/en active Active
- 2016-07-12 JP JP2016137263A patent/JP2016214248A/ja not_active Withdrawn
-
2018
- 2018-02-15 JP JP2018025362A patent/JP6758335B2/ja active Active
- 2018-04-03 CY CY20181100365T patent/CY1120113T1/el unknown
- 2018-12-29 HK HK18116749.0A patent/HK1257622A1/zh unknown
-
2019
- 2019-07-17 JP JP2019131757A patent/JP2019170400A/ja not_active Withdrawn
-
2020
- 2020-02-26 CY CY20201100179T patent/CY1122704T1/el unknown
-
2021
- 2021-07-02 JP JP2021110558A patent/JP2021169466A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086871A patent/JP2023099808A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007504830A5 (ja) | ||
JP2011092201A5 (ja) | ||
JP7002603B2 (ja) | Pd-l1発現低減用のオリゴヌクレオチド | |
JP2023113843A5 (ja) | ||
JP6758335B2 (ja) | テロメラーゼ阻害のための改変オリゴヌクレオチド | |
JP2020022483A5 (ja) | ||
JP2009524696A5 (ja) | ||
JP2019511491A5 (ja) | ||
US6583122B2 (en) | Nucleosides and oligonucleotides containing boron clusters | |
JP2016502858A5 (ja) | ||
US20030119724A1 (en) | Ligands to enhance cellular uptake of biomolecules | |
JP2015504650A5 (ja) | ||
JP2008513513A5 (ja) | ||
HRP20110352T1 (hr) | Antisens olinukleotidi za induciranje zaobilaženja egzona i postupci njihove upotrebe | |
JP2013510561A5 (ja) | ||
JP2013516190A5 (ja) | ||
JP2003523739A5 (ja) | ||
JP2016513976A5 (ja) | ||
JP2021090458A5 (ja) | ||
JP2021500025A5 (ja) | ||
JP2010505741A5 (ja) | ||
JP2009511034A5 (ja) | ||
JP2005525991A5 (ja) | ||
JP2008069182A5 (ja) | ||
JP2021072862A5 (ja) |